LivingGLP1
parallel randomized trial

S003153

Design

Randomized
360
Start year
2024
Treatment
24 weeks, follow-up 24 weeks
Countries
China (1 sites)
Sponsor
(non industry)
Eligibility
age 18 to 75; BMI 30 or more; LVEF 50 percent or more; elevated NT-proBNP

Conduct and analysis

Blinding
not reported
Sequence generation
not reported
Allocation concealment
central
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1liraglutide and dapagliflozin
Dapagliflozin plus liraglutide
lifestyle: not reported120120
A2Dapagliflozin
Dapagliflozin
lifestyle: not reported120120
A3Liraglutide 1.8 mg subcutaneous once daily
Liraglutide
lifestyle: not reported120120

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticDapagliflozin plus liraglutide
A1
Dapagliflozin
A2
Liraglutide 1.8 mg subcutaneous once daily
A3
agemean (years)57.256.857.0
agesd (years)10.59.810.3
bmimean (kg/m2)32.632.432.7
bmisd (kg/m2)2.92.72.8
egfrmean (mL/min/1.73 m2)87.588.287.8
egfrsd (mL/min/1.73 m2)15.214.915.0
hba1cmean (percent)7.57.57.6
hba1csd (percent)1.00.91.0
other malepercent52.550.853.3
sbpmean (mmHg)145.3144.8145.0
sbpsd (mmHg)15.515.215.3
weightmean (kg)89.589.789.6
weightsd (kg)11.111.311.2

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
All cause mortality (3 lines; O20)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events2 / 120not stated; randomized; R0015246:Table 3
A2events6 / 120not stated; randomized; R0015246:Table 3
A3events5 / 120not stated; randomized; R0015246:Table 3
Hospitalization for heart failure (3 lines; O23)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events6 / 120not stated; randomized; R0015246:Table 3
A2events13 / 120not stated; randomized; R0015246:Table 3
A3events11 / 120not stated; randomized; R0015246:Table 3